Important information to know – from screening to diagnosis for colorectal cancer

Tips From a Member of Our Medical Advisory Board Al B. Benson III, MD, FACP FASCO is Professor of Medicine, Feinberg School of Medicine,  and Associate Director for Clinical Investigations, Robert H. Lurie Comprehensive Cancer Center, Northwestern University One of the nation’s…  Read More

Cancer-Related Fatigue: Real, Treatable, and Under-Treated

Life-altering fatigue will affect 80% of people getting chemotherapy or radiation therapy, plus most people who have metastatic cancer, and even many survivors long after treatment is done. Yet fatigue in cancer patients has been under-reported, under-diagnosed, and under-treated, according…  Read More

Erbitux Approved as First-Line Treatment

The FDA has approved Erbitux™ (cetuximab) in combination with FOLFIRI for first-line treatment of patients with metastatic colorectal cancer whose tumors have a wild-type (WT) KRAS gene.  Erbitux was first approved in 2004 for patients whose cancer was not responding to…  Read More